• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辅助放疗在接受根治性子宫切除术的宫颈癌患者中的作用。

Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy.

作者信息

Alonso-Espías María, Gorostidi Mikel, Gracia Myriam, García-Pineda Virginia, Diestro María Dolores, Siegrist Jaime, Hernández Alicia, Zapardiel Ignacio

机构信息

Gynecologic Oncology Unit, La Paz University Hospital, 28046 Madrid, Spain.

Gynecologic Oncology Unit, Donostia University Hospital, 20014 San Sebastian, Spain.

出版信息

J Pers Med. 2023 Oct 12;13(10):1486. doi: 10.3390/jpm13101486.

DOI:10.3390/jpm13101486
PMID:37888097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10608331/
Abstract

The benefit of adjuvant radiotherapy (RT) after radical hysterectomy in patients with cervical cancer remains controversial. The aim of this study was to determine adjuvant RT's impact on survival in accordance with Sedlis criteria. Patients with early-stage cervical cancer undergoing radical hysterectomy between 2005 and 2022 at a single tertiary care institution were included. A multivariate analysis was performed to determinate if RT was an independent prognostic factor for recurrence or death. We also analysed whether there was a statistically significant difference in overall survival (OS) between patients who met only one or two Sedlis criteria, depending on whether they received adjuvant RT or not. 121 patients were included in this retrospective study, of whom 48 (39.7%) received adjuvant RT due to the presence of unfavourable pathological findings. In multivariate analysis, RT was not found to be a statistically significant prognostic factor for OS ( = 0.584) or disease-free survival (DFS) ( = 0.559). When comparing patients who met one or two Sedlis criteria, there were no statistically significant differences in OS between RT and no adjuvant treatment in either group. Since the selection of patients with cervical cancer eligible for surgery is becoming more accurate, adjuvant RT might not be necessary for patients with intermediate risk factors.

摘要

宫颈癌患者根治性子宫切除术后辅助放疗(RT)的益处仍存在争议。本研究的目的是根据Sedlis标准确定辅助放疗对生存的影响。纳入了2005年至2022年期间在一家三级医疗机构接受根治性子宫切除术的早期宫颈癌患者。进行多因素分析以确定放疗是否是复发或死亡的独立预后因素。我们还分析了仅符合一项或两项Sedlis标准的患者,根据是否接受辅助放疗,其总生存期(OS)是否存在统计学显著差异。这项回顾性研究纳入了121例患者,其中48例(39.7%)因存在不利的病理结果而接受了辅助放疗。在多因素分析中,未发现放疗是OS(P = 0.584)或无病生存期(DFS)(P = 0.559)的统计学显著预后因素。在比较符合一项或两项Sedlis标准的患者时,两组中放疗组和未接受辅助治疗组的OS均无统计学显著差异。由于 eligible for surgery 应改为 eligible for radical hysterectomy 符合根治性子宫切除术条件的宫颈癌患者的选择越来越准确,对于具有中度风险因素的患者,辅助放疗可能并非必要。 (注:原文中 eligible for surgery 表述有误,这里按照纠正后的 eligible for radical hysterectomy 翻译并添加注释说明)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db68/10608331/c78684abfd3f/jpm-13-01486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db68/10608331/c78684abfd3f/jpm-13-01486-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db68/10608331/c78684abfd3f/jpm-13-01486-g001.jpg

相似文献

1
Role of Adjuvant Radiotherapy in Patients with Cervical Cancer Undergoing Radical Hysterectomy.辅助放疗在接受根治性子宫切除术的宫颈癌患者中的作用。
J Pers Med. 2023 Oct 12;13(10):1486. doi: 10.3390/jpm13101486.
2
Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria.FIGO 2009 IB1 期宫颈癌患者行根治性子宫切除术,不辅以辅助放疗,无论 Sedlis 标准是否阳性。
Gynecol Oncol. 2021 Sep;162(3):539-545. doi: 10.1016/j.ygyno.2021.06.026. Epub 2021 Jul 10.
3
Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer.根治性子宫切除术治疗中危早期宫颈癌的辅助治疗作用。
Int J Gynecol Cancer. 2021 Jan;31(1):52-58. doi: 10.1136/ijgc-2020-001974. Epub 2020 Dec 10.
4
Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-Risk, Early-Stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy.辅助放疗对中危早期宫颈癌生存结局的影响:关于根治性子宫切除术手术方式的分析
J Clin Med. 2020 Nov 3;9(11):3545. doi: 10.3390/jcm9113545.
5
The impacts of minimally invasive surgery on intermediate- or high-risk cervical cancer patients received adjuvant radiotherapy.微创外科手术对接受辅助放疗的中高危宫颈癌患者的影响。
World J Surg Oncol. 2022 Nov 28;20(1):372. doi: 10.1186/s12957-022-02820-x.
6
The effect of adjuvant radiotherapy on oncological outcomes in patients with early-stage cervical carcinoma with only intermediate-risk factors: a propensity score matching analysis.辅助放疗对仅具有中危因素的早期宫颈癌患者肿瘤学结局的影响:一项倾向评分匹配分析
J Obstet Gynaecol. 2022 Oct;42(7):3204-3211. doi: 10.1080/01443615.2022.2109406. Epub 2022 Aug 12.
7
Risk Stratification of Early-Stage Cervical Cancer with Intermediate-Risk Factors: Model Development and Validation Based on Machine Learning Algorithm.基于机器学习算法的中危因素早期宫颈癌风险分层:模型的建立与验证。
Oncologist. 2021 Dec;26(12):e2217-e2226. doi: 10.1002/onco.13956. Epub 2021 Sep 16.
8
Comparison of outcomes between early-stage cervical cancer patients without high-risk factors undergoing adjuvant concurrent chemoradiotherapy and radiotherapy alone after radical surgery.早期宫颈癌患者无高危因素行根治术后单纯放疗与辅助同步放化疗的疗效比较。
BMC Cancer. 2024 Apr 30;24(1):548. doi: 10.1186/s12885-024-12284-9.
9
Role of adjuvant radiotherapy after radical hysterectomy in node-negative stage IB-IIA cervical cancer with intermediate risk factors.根治性子宫切除术后辅助放疗在具有中度风险因素的淋巴结阴性ⅠB - ⅡA期宫颈癌中的作用。
J Med Assoc Thai. 2012 Mar;95 Suppl 3:S117-24.
10
Treatment results of adjuvant pelvic radiotherapy after radical hysterectomy for low-risk Stage IB1-IIA cervical cancer.低风险IB1-IIA期宫颈癌根治性子宫切除术后辅助盆腔放疗的治疗结果
Jpn J Clin Oncol. 2017 Nov 1;47(11):1024-1030. doi: 10.1093/jjco/hyx127.

引用本文的文献

1
Management of Bulky Tumors in Cervical Cancer: Limits of the Surgical Approach.宫颈癌巨大肿瘤的管理:手术方法的局限性
J Clin Med. 2025 Feb 10;14(4):1142. doi: 10.3390/jcm14041142.
2
Impact of Radiotherapy on Endocrine Function and Gut Microbiota in Cervical Cancer Patients Undergoing Ovarian Transposition.放疗对接受卵巢移位术的宫颈癌患者内分泌功能和肠道微生物群的影响。
Int J Womens Health. 2024 Dec 27;16:2319-2331. doi: 10.2147/IJWH.S494268. eCollection 2024.
3
Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers.

本文引用的文献

1
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023.ESGO/ESTRO/ESP 宫颈癌管理指南-2023 年更新版。
Int J Gynecol Cancer. 2023 May 1;33(5):649-666. doi: 10.1136/ijgc-2023-004429.
2
Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years.不同术后辅助治疗对伴有 1 个中危因素的早期宫颈癌患者生存的影响:14 年多中心研究。
J Obstet Gynaecol Res. 2023 Jun;49(6):1579-1591. doi: 10.1111/jog.15632. Epub 2023 Mar 14.
3
Adjuvant pelvic radiation versus observation in intermediate-risk early-stage cervical cancer patients following primary radical surgery: a propensity score-adjusted analysis.
复发性宫颈癌的预后因素调查与分析及其影响
Cureus. 2024 Jul 25;16(7):e65361. doi: 10.7759/cureus.65361. eCollection 2024 Jul.
辅助性盆腔放疗与观察在原发性根治术后中危早期宫颈癌患者中的比较:倾向评分调整分析。
J Gynecol Oncol. 2023 Jul;34(4):e42. doi: 10.3802/jgo.2023.34.e42. Epub 2023 Feb 3.
4
Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.辅助治疗在中危宫颈癌患者中的作用 - SCCAN 研究的亚组分析。
Gynecol Oncol. 2023 Mar;170:195-202. doi: 10.1016/j.ygyno.2023.01.014. Epub 2023 Jan 25.
5
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?具有中危因素的宫颈癌根治术后辅助治疗:是时候更新了吗?
Int J Gynecol Cancer. 2022 Oct 3;32(10):1219-1226. doi: 10.1136/ijgc-2022-003735.
6
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16).塞万提斯:一项针对早期、中危宫颈癌患者的国际随机试验,比较根治性手术后辅助(化疗)放疗与不再接受进一步治疗的效果(CEEGOG-CX-05;ENGOT-CX16)
Int J Gynecol Cancer. 2022 Oct 3;32(10):1327-1331. doi: 10.1136/ijgc-2022-003918.
7
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.NCCN 指南®洞察:卵巢癌,第 3.2022 版。
J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047.
8
The effect of adjuvant radiotherapy on oncological outcomes in patients with early-stage cervical carcinoma with only intermediate-risk factors: a propensity score matching analysis.辅助放疗对仅具有中危因素的早期宫颈癌患者肿瘤学结局的影响:一项倾向评分匹配分析
J Obstet Gynaecol. 2022 Oct;42(7):3204-3211. doi: 10.1080/01443615.2022.2109406. Epub 2022 Aug 12.
9
Adjuvant therapy in early-stage cervical cancer after radical hysterectomy: are we overtreating our patients? A meta-analysis.根治性子宫切除术后早期宫颈癌的辅助治疗:我们是否过度治疗了患者?一项荟萃分析。
Clin Transl Oncol. 2022 Aug;24(8):1605-1614. doi: 10.1007/s12094-022-02808-9. Epub 2022 Apr 19.
10
Cancer of the cervix uteri: 2021 update.子宫颈癌:2021 年更新。
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):28-44. doi: 10.1002/ijgo.13865.